AtaiBeckley (ATAI) Receivables - Net (2023 - 2026)
AtaiBeckley (ATAI) recorded quarterly Receivables - Net of $864000.0 in Q1 2026, up 29.54% quarter-over-quarter from $667000.0 in Q4 2025.
AtaiBeckley (ATAI) Receivables - Net (2023 - 2026) Analysis & Trends
AtaiBeckley's Receivables - Net history runs 3 years deep, the most recent figure standing at $864000.0 for Q1 2026.
- In Q1 2026, Receivables - Net changed N/A year-over-year to $864000.0; the TTM figure through Mar 2026 stood at $864000.0 (changed N/A YoY), while the FY2025 annual figure was $667000.0, up 88.42% from the prior year.
- Receivables - Net was $864000.0 for Q1 2026 at AtaiBeckley, up from $667000.0 in the prior quarter.
- In the past five years, Receivables - Net ranged from a high of $261000.0 in Q4 2024 to a low of $46000.0 in Q1 2025.
- The 3-year median for Receivables - Net is $65000.0 (2023), against an average of $109250.0.
- Biggest YoY gain for Receivables - Net was 88.42% in 2025; the steepest drop was 88.42% in 2025.
- A 3-year view of Receivables - Net shows it stood at $354000.0 in 2024, then soared by 88.42% to $667000.0 in 2025, then gained by 29.54% to $864000.0 in 2026.
- The last three Receivables - Net figures came in at $864000.0 (Q1 2026), $667000.0 (Q4 2025), and $354000.0 (Q4 2024), per Business Quant data.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Alterity Therapeutics | 925,601.88 Bn | 925,601.85 Bn | - |
| 2 | Belite Bio | 58,560.00 Bn | 58,560.00 Bn | - |
| 3 | Quantum Biopharma | 17,284.41 Bn | 17,284.40 Bn | - |
| 4 | Legend Biotech | 2,809.00 Bn | 2,808.71 Bn | 242.10 Mn |
| 5 | Evaxion A | 1,334.43 Bn | 1,334.42 Bn | - |
| 6 | Akari Therapeutics | 1,312.27 Bn | 1,312.26 Bn | - |
| 7 | Psyence Biomedical | 212.16 Bn | 212.16 Bn | - |
| 8 | Vertex Pharmaceuticals | 114.83 Bn | 107.58 Bn | 2.59 Bn |
| 9 | Abivax | 91.96 Bn | 91.96 Bn | - |
| 10 | AtaiBeckley | 1.45 Bn | 1.45 Bn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 864,000.00 |
| Mar 31, 2026 | 864,000.00 |
| Dec 31, 2025 | 667,000.00 |
| Dec 31, 2025 | 667,000.00 |
| Sep 30, 2025 | 46,000.00 |
| Sep 30, 2025 | 46,000.00 |
| Mar 31, 2025 | 46,000.00 |
| Mar 31, 2025 | 46,000.00 |
| Dec 31, 2024 | 261,000.00 |
| Dec 31, 2024 | 261,000.00 |
| Dec 31, 2024 | 354,000.00 |
| Dec 31, 2024 | 354,000.00 |
| Dec 31, 2023 | 84,000.00 |
| Dec 31, 2023 | 84,000.00 |